Overview
- A systematic, time- and dose-based approach to acute, staggered and unclear paracetamol (acetaminophen) overdose — do not rely on symptoms alone
Key Points
- Patients can look and feel completely well in the first 24 hours despite a potentially fatal ingestion — early absence of symptoms does NOT exclude serious toxicity
- A single paracetamol level, correctly timed, drives management for a single acute ingestion — staggered/repeated ingestion and unknown-time presentations need a different approach (Section 5)
- Start NAC without waiting for the level in unknown-time, staggered, or delayed (>8h, level pending) presentations — early NAC saves lives and the risk of unnecessary treatment is low
- Stopping NAC is a clinical + biochemical decision, not a fixed-duration rule — reassess before stopping
- INR and encephalopathy, not peak transaminases, are what matter for prognosis in evolving liver failure
1 · Clinical Presentation
- Patients may be entirely asymptomatic in the first 24 hours despite a potentially serious ingestion — do not use symptom absence to reassure or discharge
- Early symptoms, when present, are non-specific: nausea, vomiting, anorexia, malaise, diaphoresis, pallor
Clinical Features by Time Since Ingestion
| Phase | Typical Features |
|---|---|
| 0–24 hours | Often asymptomatic, or mild nausea/vomiting, anorexia, malaise — no reliable clinical marker of severity at this stage |
| 24–72 hours | GI symptoms may resolve or persist · RUQ pain and tenderness develops · hepatic transaminases begin to rise · this is when hepatotoxicity typically becomes biochemically apparent |
| 72–96 hours | Peak hepatotoxicity — transaminases, bilirubin and INR often peak in this window · jaundice · worsening RUQ pain · may progress to overt liver failure: coagulopathy, encephalopathy, acidosis, renal impairment, hypoglycaemia |
| > 96 hours | Resolution with recovery of hepatic function in survivors of significant injury, OR progression to multi-organ failure/death in severe cases · recovery, when it occurs, is typically complete |
Features Suggesting Evolving Hepatic Failure
- Persistent vomiting · RUQ pain and tenderness · jaundice
- Rising INR/PT · rising bilirubin · hypoglycaemia
- Any change in mental status — even mild confusion may be early encephalopathy
Features Suggesting Severe Toxicity / Critical Illness
- Altered mental status, confusion, agitation, or decreased consciousness (encephalopathy)
- Marked coagulopathy/bleeding
- Metabolic/lactic acidosis, hypotension, oliguria
- Hypoglycaemia
- Multi-organ dysfunction
2 · Defining the Overdose
- Potentially toxic single acute ingestion (adult, no risk factors): ≥150 mg/kg OR ≥10 g (whichever is LOWER), taken within a short period (practically, within about 1 hour)
- Risk factors for hepatotoxicity (lower the threshold of concern and may increase susceptibility at a given level): chronic excess alcohol use · chronic malnutrition or fasting state/eating disorders · low body weight · chronic liver disease · enzyme-inducing medication (e.g. phenytoin, carbamazepine, rifampicin, chronic isoniazid) · HIV infection. Risk-factor status is often unreliable from history alone — when in doubt, treat as higher risk and seek toxicology/specialist advice
- Single acute ingestion: one ingestion, or several doses within about 1 hour — the Rumack–Matthew nomogram can be used if timing is reliable (Section 4)
- Staggered / repeated supratherapeutic ingestion: doses taken over more than 1 hour, typically over several hours to days, often exceeding recommended therapeutic dosing — the nomogram CANNOT be used (Section 4). Treat based on cumulative dose and biochemical evidence of toxicity, not a single timed level
- Therapeutic misadventure: unintentional supratherapeutic dosing, often in the context of pain management or multiple combination products — assess cumulative 24-hour dose and duration the same way as staggered ingestion
- Unknown time of ingestion: the nomogram cannot be reliably applied — manage as high risk and do not wait for a timed level before involving toxicology (Section 5)
- Interpretation of a paracetamol level always depends on the timing and the ingestion pattern — the same level can mean very different things in a 4-hour single acute ingestion versus a 3-day staggered ingestion. Do not apply nomogram-based reassurance to a staggered or unknown-time presentation
3 · History
- Exact or best-estimate time of ingestion
- Maximum possible amount ingested (assume the worst-case/maximum stated amount)
- Formulation and strength (mg per tablet, liquid concentration)
- Immediate-release vs modified/extended-release preparation — modified-release changes nomogram interpretation and level timing (Section 5)
- Single ingestion vs repeated/staggered dosing, with timing of each dose if possible
- Other medications and co-ingestants (especially opioids, anticholinergics/antihistamines, or agents that delay gastric emptying)
- Alcohol use — acute and chronic
- Therapeutic paracetamol use in the preceding days
- Risk factors for hepatotoxicity (Section 2)
- Intent — intentional vs accidental ingestion; complete an appropriate mental-health/risk assessment for intentional self-poisoning
4 · Examination
- Vital signs
- GCS / mental status — repeat, do not assess once only
- Hydration status
- Abdominal examination — RUQ tenderness
- Evidence of hepatic dysfunction: jaundice, asterixis
- Signs of encephalopathy
- Signs of shock or multi-organ failure
5 · Investigations
| Test | Why |
|---|---|
| Serum paracetamol concentration | Correctly timed, drives nomogram-based decisions for single acute ingestion (Section 6) |
| ALT / AST | Hepatocellular injury — baseline and trend |
| Bilirubin | Hepatic dysfunction; rises with worsening injury |
| ALP / GGT (where appropriate) | Supportive hepatic picture, helps exclude other causes |
| INR / PT | The single most important prognostic marker alongside encephalopathy |
| U&E / creatinine | Renal function — part of King's College Criteria; AKI accompanies severe toxicity |
| Glucose | Hypoglycaemia is a marker of severe hepatic dysfunction — check regularly |
| FBC | Baseline; bleeding/coagulopathy assessment |
| Venous or arterial blood gas | Acid–base status; lactate when indicated |
| Lactate | When clinically indicated — part of modified prognostic assessment (Section 11) |
| Electrolytes | Baseline and ongoing monitoring |
| Pregnancy test (where appropriate) | Affects disposition/counselling; does not change NAC indication |
| Salicylate level (where appropriate) | Common co-ingestant — screen when history uncertain or mixed-tablet ingestion |
| Ethanol level (where appropriate) | Co-ingestant; affects mental status assessment |
| Other investigations | Guided by suspected co-ingestants (e.g. ECG for cardiotoxic drugs) |
When to Take the Paracetamol Level
- Single acute ingestion, time known, presents ≥4 hours after ingestion: send a level immediately and plot on the nomogram (Section 6)
- Presents <4 hours after ingestion: a level taken before 4 hours cannot be reliably interpreted (absorption may be incomplete) — send a level AT 4 hours post-ingestion (not immediately), and consider activated charcoal if presenting within ~1–2 hours and a significant ingestion is likely
- Time of ingestion unknown: the nomogram cannot be used reliably — send a level plus LFTs/INR immediately, treat as high risk, and start NAC without waiting for results if there is any suggestion of a potentially toxic ingestion (Section 7)
- Staggered / repeated supratherapeutic ingestion: a single timed level and the nomogram DO NOT apply — send a level plus ALT/AST and INR; base the decision to treat on cumulative dose and any biochemical evidence of toxicity (Section 7), not on where a level falls on the nomogram
- Modified/extended-release preparation: absorption is delayed and prolonged — send a level at 4 hours, then repeat at 4-hour intervals (e.g. 4h and 8h) as very early levels may underestimate peak concentration; have a lower threshold to start NAC and seek toxicology advice
- Prolonged delay before presentation (>24 hours): send a level, ALT/AST, INR and renal function immediately — do not rely on the nomogram beyond its validated window (Section 6); start NAC immediately if there is any evidence of hepatotoxicity or a plausible toxic ingestion, do not wait for nomogram interpretation
6 · Rumack–Matthew Nomogram — When It Can and Cannot Be Used
- CAN be used for: a single acute ingestion with a known or confidently estimated ingestion time, with a level drawn between 4 and 24 hours post-ingestion
- CANNOT be used for: staggered or repeated supratherapeutic ingestion · unknown or unreliable time of ingestion · a level drawn before 4 hours · presentations where the time since ingestion is not credible
- Treatment line used by this protocol: a single treatment line of 200 mg/L (1324 μmol/L) at 4 hours, falling to approximately 6.25 mg/L at 24 hours (halving roughly every 4 hours) is the classic Rumack–Matthew 'probable-risk' line; many current protocols instead use a lower, more conservative single treatment line of 100–150 mg/L at 4 hours with no separate high-risk sub-line. This protocol uses the more conservative single treatment line: treat if the 4-hour-equivalent level is at or above approximately 150 mg/L (≈1000 μmol/L), falling proportionally thereafter. If your service uses a locally-adopted lower single line (e.g. 100 mg/L at 4 hours), follow that local line — it is simply a more cautious variant of the same approach
- A formerly separate 'high-risk' treatment line for patients with risk factors (Section 2) has largely been abandoned because risk-factor status is often unreliable from history — instead, treat risk-factor-positive patients with a lower threshold of clinical suspicion around the single line, and involve toxicology early if the level is borderline
- Result at or above the treatment line → START NAC (Section 7). Result below the line in a confirmed single acute ingestion, correctly timed, with no clinical/biochemical evidence of toxicity → NAC not required on nomogram grounds alone
Nomogram — Approximate Treatment Line (for reference)
- 4 hours: ≈150 mg/L (1000 μmol/L)
- 8 hours: ≈75 mg/L (500 μmol/L)
- 12 hours: ≈37 mg/L (250 μmol/L)
- 16 hours: ≈19 mg/L (125 μmol/L)
- 20 hours: ≈9 mg/L (62 μmol/L)
- 24 hours: ≈5 mg/L (31 μmol/L)
- This is an approximate exponential decay for illustration — always plot the actual level against time on a validated nomogram chart rather than relying on these rounded reference points.
🚨 START NAC — Treatment Indications
- Paracetamol level at or above the treatment line on the nomogram, correctly plotted for a single acute ingestion with reliable timing
- Unknown or unreliable time of ingestion with a potentially toxic amount reported — do not wait for a timed level
- Staggered or repeated supratherapeutic ingestion that meets or exceeds a potentially toxic cumulative dose (Section 2), OR any biochemical evidence of toxicity (paracetamol detectable AND ALT/AST or INR abnormal, or clinical features of toxicity)
- Delayed presentation (>8 hours since a known single acute ingestion) where the level will not be available within 8 hours of ingestion — start NAC immediately while awaiting the level; stop early only if the level, once available, is below the treatment line AND LFTs/INR are normal
- Any evidence of liver injury (elevated ALT/AST, abnormal INR) attributable to paracetamol, regardless of the current level
- Clinical features of hepatotoxicity in a patient with a plausible paracetamol overdose history
- Do NOT delay starting NAC while awaiting laboratory results in any high-risk scenario above — the risk of a short course of unnecessary NAC is low; the risk of delayed treatment in true toxicity is high
- NAC is most effective when started within 8 hours of ingestion, but still provides significant benefit when started later — including in patients who already have established hepatic injury. Never withhold NAC solely because of a delayed presentation.
7 · IV N-Acetylcysteine (NAC) Dosing — Standard 3-Bag / 21-Hour Regimen
| Infusion | Dose | Diluent volume (adult) | Duration |
|---|---|---|---|
| 1st infusion (loading) | 150 mg/kg IV | 200 mL (5% dextrose or 0.9% saline) | over 60 minutes |
| 2nd infusion | 50 mg/kg IV | 500 mL | over 4 hours |
| 3rd infusion | 100 mg/kg IV | 1000 mL | over 16 hours |
NAC Dosing — Practical Notes
- Total dose over the standard course: 300 mg/kg over 21 hours
- Weight used for dosing is capped at 110 kg — do not calculate NAC dose using actual body weight above 110 kg; use 110 kg as the maximum
- Low body weight: dose by actual weight; in small adults/adolescents, use paediatric-concentration preparations if available to avoid excessive fluid volume, and seek toxicology/pharmacy advice on diluent volume
- A modified 2-bag/12-hour regimen (e.g. 100 mg/kg over 2 hours, then 200 mg/kg over 10 hours — same total 300 mg/kg) is used by some services and is associated with fewer anaphylactoid reactions with similar efficacy; use whichever regimen is adopted locally — do not mix infusion rates from different regimens
- Massive overdose may require intensified NAC dosing — see Section 15
8 · NAC Adverse Reactions
- Nausea/vomiting: common, especially during the loading infusion — slow the infusion rate, treat with antiemetic; do not stop NAC for GI symptoms alone
- Anaphylactoid reaction (flushing, urticaria, angioedema, bronchospasm, hypotension) occurs in a meaningful minority, most often during the loading infusion, and is dose/rate-related histamine release — NOT true IgE-mediated anaphylaxis
- Mild reaction (rash/flushing only): pause the infusion, give an antihistamine, restart at a slower rate once symptoms settle
- Moderate–severe reaction (bronchospasm, angioedema, hypotension): stop the infusion, treat per anaphylaxis protocol (antihistamine ± bronchodilator ± adrenaline if significant bronchospasm/hypotension), stabilise the patient, then restart NAC at a slower infusion rate once the patient is stable — do not permanently abandon NAC if it is still indicated; continued/resumed treatment is almost always required
- NAC should essentially always be restarted after stabilisation given the risk of untreated toxicity outweighs the risk of a recurrent reaction at a slower rate; discuss difficult cases with toxicology
🛑 9 · NAC Completion & Stopping Criteria — DO NOT Use a Fixed Duration Alone
- Reassess clinically and biochemically at/near completion of the standard course — do not stop purely because the infusion timer has finished
- Check before considering stopping: repeat paracetamol concentration · ALT/AST · INR/PT · creatinine/U&E · glucose · clinical status (mental state, vomiting, abdominal pain)
- NAC CAN be stopped when ALL of the following are satisfied: paracetamol concentration is low/undetectable AND ALT/AST is normal or clearly improving and not more than approximately 2× the admission value AND INR ≤1.3 AND the patient is clinically well
- NAC must be CONTINUED (extend beyond the standard course) if: paracetamol remains significantly detectable, OR ALT/AST is rising or rising toward/above the threshold above, OR INR is abnormal or rising, OR there is any clinical evidence of hepatic injury or encephalopathy, OR lactate remains elevated, OR there is renal impairment attributable to paracetamol toxicity, OR the patient remains clinically unstable
- When continuing: repeat the 100 mg/kg/16-hour infusion (or continue the equivalent maintenance infusion) and re-check bloods before each subsequent infusion ends, continuing until the stopping criteria above are met or INR is clearly improving with two consecutive falling results
- Involve toxicology/hepatology early if NAC is being extended beyond the standard course, or if any stopping-criterion result is abnormal and not clearly improving
10 · Monitoring During Treatment
- Vital signs — frequency according to severity
- Fluid balance
- Neurological status — repeated GCS/mental status checks; a falling GCS or new confusion is a red flag for encephalopathy
- Glucose — regularly; hypoglycaemia signals severe hepatic dysfunction
- Liver function tests and INR — repeat at intervals appropriate to severity (more frequently in significant toxicity)
- Renal function
- Acid–base status / lactate when clinically indicated
- ECG/telemetry when clinically appropriate (e.g. co-ingestant, electrolyte disturbance, haemodynamic instability)
- Increase the frequency of repeat bloods in any patient with rising transaminases, abnormal INR, or clinical deterioration
🚨 11 · Recognising Acute Liver Failure
- Hepatic encephalopathy (any grade — repeated assessment is essential)
- Coagulopathy (rising INR/PT)
- Hypoglycaemia
- Metabolic/lactic acidosis
- Acute kidney injury
- Hyperbilirubinaemia
- Markedly elevated transaminases
- Haemodynamic instability
- Cerebral oedema / signs of intracranial hypertension in severe cases
- INR and the presence/grade of encephalopathy are the key prognostic markers — a very high ALT/AST alone does NOT determine prognosis and should not be used in isolation to reassure or to escalate
🚨 12 · CALL HEPATOLOGY / LIVER TRANSPLANT CENTRE — King's College Criteria
- Refer/discuss if EITHER:
- (A) Arterial pH < 7.3 (after adequate fluid resuscitation) — this alone is sufficient
- — OR —
- (B) ALL THREE of: INR > 6.5 (PT > 100 s) AND creatinine > 300 μmol/L (≈ >3.4 mg/dL) AND grade III–IV encephalopathy
- Early adjunct markers (increase sensitivity, support earlier recognition): arterial lactate > 3.5 mmol/L measured ~4 hours after initial fluid resuscitation suggests a poor prognosis even before criteria A/B are met; later (~12 hours after admission), pH < 7.3 OR lactate > 3.0 mmol/L is also a validated poor-prognosis marker
When to Discuss Early — Do Not Wait for Formal Criteria
- Contact the regional liver/transplant service EARLY, as soon as acute liver failure is evolving — do not wait until formal transplant criteria above are fully met
- Early discussion is warranted for: clinical deterioration · any new or worsening encephalopathy · progressive coagulopathy (rising INR trend) · persistent acidosis or lactataemia · renal failure · shock · multi-organ dysfunction
- Early referral allows timely transfer — deterioration in paracetamol-induced liver failure can be rapid
13 · ICU / HDU Referral
- Grade III–IV hepatic encephalopathy
- Airway compromise (unable to protect airway)
- Shock / vasopressor requirement
- Severe metabolic acidosis
- Persistently elevated lactate
- Severe hypoglycaemia
- Significant acute kidney injury
- Concern for cerebral oedema
- Multi-organ failure
14a · Discharge from ED
- Appropriate assessment and treatment completed
- Paracetamol level appropriately interpreted for the ingestion pattern (not simply because the patient feels well)
- No evidence of hepatic injury requiring continued treatment
- If NAC was given, it was discontinued according to the validated stopping criteria above (Section 9) — not simply because the standard infusion duration elapsed
- Relevant bloods (LFTs, INR) normal or stable and appropriately trending
- Clinically well, with no ongoing toxicity
- Appropriate mental-health/risk assessment completed after any intentional overdose, with a safety plan
- Safe social circumstances and follow-up arranged where required
- Do NOT discharge a patient solely because they are asymptomatic — asymptomatic status in the first 24–72 hours does not exclude significant toxicity
14b · Medical Admission
- Significant ingestion requiring NAC
- Abnormal LFTs
- Abnormal INR
- Persistently detectable paracetamol level
- Delayed presentation with an ingestion of concern
- Staggered/repeated supratherapeutic ingestion meeting treatment criteria
- Significant co-ingestion requiring observation/treatment
- Any clinical deterioration
14c · Liver / Transplant Centre Transfer
- Any patient meeting, or approaching, King's College Criteria (Section 12)
- Evolving encephalopathy of any grade
- Progressive coagulopathy
- Persistent acidosis, elevated/rising lactate, or renal impairment in the context of significant hepatotoxicity
- Any patient where the treating team and hepatology/transplant centre jointly agree transfer is appropriate — discuss early rather than waiting for deterioration
15 · Special Situations
- Unknown time of ingestion: manage as high risk; send level + LFTs/INR immediately; start NAC without waiting for results if a potentially toxic ingestion is plausible
- Staggered ingestion: nomogram does not apply; base treatment on cumulative dose and biochemical evidence of toxicity (Sections 2 and 7)
- Repeated supratherapeutic ingestion: as above — treat even if a single level looks reassuring if the ALT/AST or INR is abnormal
- Modified-release preparations: delayed/prolonged absorption — repeat levels at 4-hour intervals, lower threshold to treat, involve toxicology
- Massive ingestion: see Section 16 — standard NAC may be inadequate
- Delayed presentation: treat based on current evidence of toxicity, not retrospective nomogram placement beyond its validated window; NAC still provides benefit even late
- Pregnancy: treat the mother per standard criteria — NAC is the standard of care in pregnancy and protects both mother and fetus; do not withhold or delay NAC because of pregnancy
- Chronic alcohol use: lowers the threshold of clinical concern (Section 2); manage alcohol withdrawal risk concurrently
- Malnutrition / low body weight / eating disorders: increased susceptibility to hepatotoxicity — lower threshold to treat and to involve toxicology
- Patients already taking therapeutic paracetamol: consider cumulative dosing when assessing an additional reported overdose
- Co-ingestion with opioids or anticholinergic drugs: delayed gastric emptying can delay and prolong paracetamol absorption — repeat levels, lower threshold to treat, longer observation
- Established acute liver failure at presentation: start/continue NAC regardless of time since ingestion or current level — involve hepatology/toxicology immediately
16 · Massive Paracetamol Overdose
- Definition used here: ingestion of approximately ≥30 g, OR a level mapping to ≥2× the treatment line (i.e. at/above the classic 'possible-risk' 300 mg/L-equivalent line at 4 hours)
- Standard NAC dosing and standard monitoring intervals may be inadequate in massive overdose — early metabolic/lactic acidosis and multi-organ dysfunction can develop within hours, well before the classic 72–96 hour hepatotoxicity window
- Involve toxicology and hepatology early for any massive ingestion
- Intensified NAC dosing (e.g. increasing the maintenance infusion rate/dose) has been proposed and is used by some toxicology services for massive overdose with early acidosis or markedly elevated levels — this is not a single universally standardised regimen; seek toxicology advice rather than empirically escalating the dose without guidance
- Monitor venous/arterial lactate and acid–base status closely and early in massive overdose, even before the usual hepatotoxicity window
17 · Quick ED Algorithm
Suspected paracetamol overdose
↓
Establish time of ingestion + maximum amount + ingestion pattern (single / staggered / unknown)
↓
Send bloods: paracetamol level (correctly timed) + ALT/AST + INR + U&E/creatinine + glucose
↓
Single acute ingestion, known time, level ≥4h: plot on nomogram
↓
Staggered / unknown time / delayed presentation: do NOT use nomogram → assess cumulative dose + biochemistry
↓
Level/history meets treatment criteria? → START NAC
↓
Monitor: mental status · glucose · LFTs · INR · renal function
↓
Reassess at/near course completion — repeat level, ALT/AST, INR
↓
Stopping criteria met? → STOP NAC : Ongoing toxicity? → CONTINUE NAC, repeat bloods, reassess again
↓
Any encephalopathy, coagulopathy, acidosis, AKI, hypoglycaemia? → Recognise acute liver failure
↓
Meets or approaches King's criteria, or deteriorating? → CALL HEPATOLOGY / TRANSPLANT CENTRE early + consider ICU
↓
Disposition: Discharge (criteria met) / Admit (ongoing treatment or abnormal bloods) / Transfer (liver failure)
Do Not Miss
- Do not reassure or discharge based on the patient being asymptomatic
- Do not apply the nomogram to a staggered, repeated, or unknown-time ingestion
- Do not take a level before 4 hours and interpret it as reassuring
- Do not stop NAC purely because the standard infusion duration has elapsed
- Do not rely on peak ALT/AST alone for prognosis — INR and encephalopathy matter more
- Do not delay NAC while waiting for a level in a high-risk/delayed/unknown-time presentation
- Do not withhold or permanently stop NAC after a mild/moderate anaphylactoid reaction if treatment is still indicated
- Do not forget a mental-health/risk assessment after intentional ingestion
- Do not wait for formal King's College Criteria to be fully met before contacting the liver/transplant centre if the patient is deteriorating
- Do not forget co-ingestants, especially agents that delay gastric emptying or are independently toxic